Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors&apos; reply.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Aug 2020

Volume: 21

Issue: 8

Affiliations

[1 ] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

[2 ] Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA; Agios Pharmaceuticals, Cambridge, MA, USA.

[3 ] Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China. Electronic address: azhu@mgh.harvard.edu.

Article

Publisher Item ID: S1470-2045(20)30394-6

DOI: 10.1016/S1470-2045(20)30394-6

PubMed ID: 32758466

SO-VID: b944c850-d36b-4704-8773-ebc2862112c3

History

Data availability:

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.

Read this article at

Related collections

ScienceOpen Research

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 2,352

Cited by 1